| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8c0041e35a599d9aaff86f983968889f |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-507
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-54
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-525
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-57
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-065
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-118
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6893
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6883
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-244 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
| filingDate |
2014-05-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_049320df0f1a5b21a9f71c0e726a785b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_56e969487bf18d59311cd4d4b4ca6b8f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_84822099629f08dc8564b91407cffa09 |
| publicationDate |
2016-04-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2016096885-A1 |
| titleOfInvention |
Distinct effects of ifn-gamma and il-17 on tl1a modulated inflammation and fibrosis |
| abstract |
Described herein are methods and compositions related to Inflammatory Bowel Disease. Specifically TL1A drives regional intestinal inflammation and fibrosis and is differentially modulated by IFN gamma and IL-17a. In one embodiment, the present invention is a method of diagnosing a condition in a subject by determining the presence or absence of IFN gamma and/or IL-17 and diagnosing the subject. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11312768-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10316083-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11186872-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11434296-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10633449-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11236393-B2 |
| priorityDate |
2013-05-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |